Citations

Clear

2 citation(s) found for "Su, Danchen".

Tunneling nanotube–mediated intercellular filamin A transport mechanosensitively programs osteoclastogenesis in myeloma bone disease
Guo, Jing , Wang, Jingjing , Xie, Ying , Wang, Yixuan , Peng, Ziyi , Cheng, Hao , Li, Tiantian , Jia, Linchuang , Xu, Hongwei, Su, D, Qiao, Mu, Li, Keqing, Li, Wenjing , Wu, Di, Huang, Jianyong, Li, F., Zhao, Zhigang, Cheng, Hao , Li, Tiantian , Li, Wenjing , Huang, Jianyong , Bergsagel, P. Leif , Li, Feng , Liu, Zhiqiang , Wang, Mengqi, Su, Danchen, Liu, Huanhuan, Li, Xinyang, Bergsagel, P. Leif , Liu, Zhiqiang , Peng, Ziyi

Mayo Clinic

Blood | April 8, 2026 | Volume: 148 | Issue: 5 | Pages: 581-597

10.1182/blood.2025031627 | PMID 41950002 Get It

Abstract Intercellular communication between multiple myeloma (MM) cells and osteoclast precursor cells (pre-OCs) contributes extensively to the occurrence and development of myeloma-related bone destruction. However, key interacting modes and the exchanged substances involved in this communication remain unclear. In this study, we discover that tunneling nanotubes (TNTs) directly connect MM and pre-OCs. Using the stable isotope labeling with amino acids in cell culture assay and a positive-negative double selection strategy, we identify filamin A (FLNA) as a major protein transported from MM to pre-OCs. FLNA acts as a molecular clutch linking extracellular matrix–bound MAC1 to the cytoskeleton, activating Rho and MAPK signaling pathways and promoting F-actin polymerization, which subsequently enhances osteoclast differentiation by modulating cellular stiffness, traction force, and deformability. In addition, FLNA directly binds vinculin and promotes its recruitment to podosomes, thereby enhancing the functions of podosomes and the bone resorption capacity of osteoclasts. The conditional depletion of Flna in mice suppresses podosome activity and reduces stiffness, traction force, and deformability in pre-OCs, leading to significantly impaired osteoclast differentiation and increased bone mass. In the Vk∗MYC mouse model of myeloma, the administration of the TNT inhibitor latrunculin B disrupts FLNA transport to osteoclasts and alleviates osteolytic bone disease. These findings highlight the critical role of MM-transferred FLNA in osteoclastogenesis and suggest that targeting TNTs may represent a therapeutic strategy to limit pathological bone resorption associated with MM.
Prevalence of Hidradenitis Suppurativa
Hagan, Paa Gyasi, Botvid, Sofia , Hove, Lone Storgaard, Christensen, Robin , Group, GHiSA, Knecht-Gurwin, Klaudia , Zobiri, S., Serradj, A. , Noor, Towhida , Guillem, Philippe , Parvizi, Mohammad Mahdi , Vardar, Caner, Maharbi, Waleed H. A. Al, Huijstee, Johanna C. van , Aarts, Pim , Dewi, Shinta Trilaksmi , Indrastuti, Niken , Suryawati, Nyoman , Adji, Aryani , Akhyar, Gardenia , Nopriyati, Nopriyati, Reyes‐Baraona, Francisco, Matas, Carlos, Saeed, Haroon , Moodley, Ameshin , Binamer, Yousef , Kamil, Moonyza Akmal Ahmad , Jocic, Ivana , Mijušković, Željko, Mallawaarachchi, Kanchana , Gangani, Chathurika, Tusheva, Ivana , Boshkovski, Vesna Brishkoska , Hu, Danchen , Medianfar, Cecilia E. , Benhadou, Farida , Naik, Haley B. , Boer, Jurr , Bouazzi, Dorra , Nielsen, Sabrina Mai , Prens, Errol P. , Jemec, Gregor B. E. , Group, GHiSA, Szepietowski, Jacek C. , Anaba, Ehiaghe L. , Chehad, Ahmed Samaouel , Bhuiyan, Mohammed Saiful Islam , Saki, Nasrin , Alpsoy, Erkan , Kanni, Theodora , Giamarellos‐Bourboulis, Evangelos J. , Frew, John W. , Maharbi, Waleed AL, Febriana, Sri Awalia , Pangastuti, Miranti , Nopriyati, Nopriyati , Hazlianda, Cut Putri , Matas, Carlos, Saeed, Haroon, Geng, Songmei , Saunte, Ditte Marie Lindhardt , Chandran, Nisha Suyien , Zee, Hessel H. van der , Zouboulis, Christos C. , Villumsen, Bente , Alavi, Afsáneh , Ibekwe, Perpetua U. , Hamzavi, Iltefat H. , Ingram, John R , Garg, Amit

Mayo Clinic

JAMA Dermatology | August 27, 2025 | Volume: 161 | Issue: 10 | Pages: 1022

10.1001/jamadermatol.2025.2373 | PMID 40864454 Get It

Importance Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with a substantial burden. Standardized global prevalence estimates and data on associated sociodemographic and risk factors are lacking. Objective To estimate the global prevalence of HS and study differences in prevalence by age, sex, geographical location, body mass index (BMI; calculated as weight in kilograms divided by height in meters squared), smoking status, gross domestic product (GDP), and Human Development Index (HDI). Data Sources and Study Selection Included studies were conducted using the standardized Global Hidradenitis Suppurativa Atlas methodology with finalized data collection before May 19, 2023. Studies were required to use a population-based sampling method and conduct clinical confirmation of HS diagnosis following a screening questionnaire. Data Extraction and Synthesis Data were independently extracted from relevant studies by 2 reviewers (D.B. and C.E.M.) using a standardized form. Extracted variables included geographic location, age, sex, BMI (median and BMI >30), smoking status, HS prevalence estimates (with 95% CIs), GDP, and HDI. A proportional meta-analysis using a random-effects model was conducted on the included studies. Main Outcomes and Measures The primary outcome was the point prevalence of HS, confirmed by clinical examination. Secondary outcomes included differences in HS prevalence by sex, age, BMI category, smoking status, and country-level socioeconomic indicators (GDP and HDI). All outcomes were prespecified before data analysis. Results The sample included 22 743 participants, identifying 247 patients with HS, across 25 studies in 23 countries spanning 6 continents. The median proportion of female patients with HS was 55.6%, and the median age was 34.5 years. While the prevalence estimates showed considerable inconsistency ( I 2 > 75%; τ 2 = 0.747), the overall random-effects global prevalence of HS was 0.99% (95% CI, 0.67%-1.46%). Female sex was the only factor observed to be associated with the prevalence estimates (β = 1.02; 95% CI, 1.01-1.03). Conclusions and Relevance In this meta-analysis, an estimated global prevalence of HS between 0.67% and 1.46% surpassed previous global estimates. Substantial global variations in HS prevalence were also observed. Female sex was the only factor associated with prevalence in this sample. Future studies assessing genetic, environmental, and etiological factors are warranted to explain the heterogeneity in prevalence.